London’s AIM All Share started the day with some positive momentum but this proved short-lived and the junior index was trading in negative territory by our early copy time. Whilst US rate cuts are expected later this week, there’s concern that this will in turn fuel inflationary pressures. By 3pm, the index was around one point lower at 767.56.
- Renalytix +92%
- Sunrise Resources +35%
- Crism Therapeutics +16%
- Distil -23%
- ECR Minerals -22%
Renalytix LON:RENX was topping the board at copy time, up by 92% following news of a distribution agreement with US-based Tempus AI. This is seen as offering accelerated reach into the US market where as many as 15million patients could benefit from Renalytix diagnostics.
Sunrise Resources LON:SRES was 35% higher at copy time with the company having released two project updates today. These include mineral deposit samples being provided to a prospective customer and the company’s Hazen project in Nevada has been approved paving the way for a possible bid for the site from a large US-based company.
Crism Therapeutics [LON:CRTX] was 16% higher off the back of an interim report. There was little new detail here and volumes were thin, with the gain being little more than the quoted spread.
Distil LON:DIS was the biggest faller as we went to press, down 23%. That comes off the back of a discounted funding round although significant commitment here from major shareholders may have helped lessen the blow. The company continues to evaluate the best way to deliver best shareholder value.
ECR Minerals LON:ECR was in second to last place trading down 22%. That’s despite the release of drill results this morning which were seen as exceeding expectations, along with news that potential partners were coming forward.
Comments (0)